Trials / Conditions / Carcinoma, Small Cell Lung

Carcinoma, Small Cell Lung

24 registered clinical trials studyying Carcinoma, Small Cell Lung — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Safety Study of 212Pb-Pentixather Radioligand Therapy NCT05557708	Yusuf Menda	EARLY_Phase 1
Recruiting	Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherap NCT07476287	Pfizer	Phase 2
Recruiting	Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients NCT07242547	Fundación GECP	Phase 2
Withdrawn	Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs NCT04985357	Travera Inc	—
Active Not Recruiting	A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Do NCT05566041	EpicentRx, Inc.	Phase 3
Terminated	A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer NCT04308785	Hoffmann-La Roche	Phase 2
Completed	Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Pa NCT04622228	Hoffmann-La Roche	Phase 2
Unknown	Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lu NCT04253145	Fundacion Oncosur	Phase 1 / Phase 2
Unknown	Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer NCT03871205	Shenzhen People's Hospital	Phase 1
Terminated	RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Sm NCT03699956	EpicentRx, Inc.	Phase 3
Completed	BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer NCT03083691	Lung Cancer Group Cologne	Phase 2
Completed	PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Ca NCT02936323	Tarveda Therapeutics	Phase 1 / Phase 2
Unknown	HS-WBRT for Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer NCT02736916	General Hospital of Ningxia Medical University	N/A
Terminated	To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Partic NCT01284348	Merck Sharp & Dohme LLC	Phase 2
Completed	Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and NCT01306045	National Cancer Institute (NCI)	Phase 2
Completed	Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer NCT00923884	National Cancer Institute (NCI)	—
Terminated	N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy NCT00637624	Rijnstate Hospital	N/A
Terminated	Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma NCT00435578	Threshold Pharmaceuticals	Phase 2
Completed	Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung NCT00308529	SCRI Development Innovations, LLC	Phase 2
Completed	Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer NCT00294931	SCRI Development Innovations, LLC	Phase 2
Completed	Metabolomic Analysis of Lung Cancer NCT00263731	University of Louisville	—
Terminated	Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer NCT00265200	University of Louisville	Phase 2
Completed	Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinat NCT00037713	Eli Lilly and Company	Phase 3
Completed	The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy NCT00270166	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3